Generic Name and Formulations:
Chlorzoxazone 375mg, 750mg+; tabs; +scored.
Various generic manufacturers
Indications for Chlorzoxazone:
As adjunct to rest, physical therapy, and other measures in acute, painful musculoskeletal conditions.
375mg: 1 tab 3–4 times daily; may increase to 2 tabs (750mg) 3–4 times daily if inadequate response. 750mg: ⅓ tab (250mg) 3–4 times daily. Painful musculoskeletal conditions: initially ⅔ tab (500mg) 3–4 times daily; may increase to 1 tab (750mg) 3–4 times daily if inadequate response. May reduce dose based on improvement.
Known drug intolerance.
Monitor for hepatotoxicity; discontinue if hepatic dysfunction or abnormal liver enzymes develop. Known allergies or history of. Discontinue if sensitivity reaction occurs. Pregnancy.
Additive effects with concomitant alcohol, other CNS depressants.
Muscle relaxant (central).
Drowsiness, dizziness, lightheadedness, malaise, overstimulation; rare: skin rash, petechiae, ecchymosis, fatal hepatocellular toxicity.
Formerly known under the brand name Lorzone.
Clinical Pain Advisor Articles
- Sustained-Release Sodium Nitrite for Diabetic Neuropathic Pain Not Associated With Headaches
- Treatment for Opioid Use Disorder Associated With Reduced Risk for Opioid-Related Deaths
- Deaths After Nonfatal Opioid Overdose: Causes and Risk Factors
- Clonidine May Not Improve Post-Cesarean Delivery Analgesia
- No Added Value With Liposomal Bupivacaine Following TKA With Peripheral Nerve Block
- Recommendations for Perioperative Pain Management in Patients With Opioid Tolerance
- Vertebroplasty Comparable With Placebo for Acute Vertebral Compression Fractures
- Capsaicin 8% Patch May Be Effective in Neuropathic Pain
- Detox vs Medication-Assisted Treatment for Opioid Use Disorder in Pregnancy: Expert Roundtable
- Prior Authorization Policy May Help Reduce Long-Acting Opioid Use
- Opioid-Related Deaths Represent Significant Public Health Burden
- Addressing Confidentiality Concerns With Electronic Access to Pediatric Medical Records
- Opioid-Related Adverse Events Common After Invasive Procedures
- Diagnosis and Treatment of Migraine in Children Should Consider Atopy
- Led by AG Sessions, DOJ Declines to Defend ACA Against Federal Lawsuit